Key Takeaways from IDWeek 2025: AI, AMR Strategies, Next-Generation Anti-Viral Development Converging
IDWeek 2025 marked a pivotal moment in the evolution of infectious diseases (ID) research and pharmaceutical innovation. Beyond its traditional...
Medpace Expands Medical Leadership Team with Expert in Parkinson’s Disease
Neuroscience and Cognition and brings extensive expertise in the design and execution of Parkinson’s disease research. Additionally, she has over...
Redefining Midlife Care – Clinical Development Imperatives for Perimenopause, Menopause, and Postmenopausal | World Menopause Day
Menopause remains one of the most underrepresented areas in clinical research. Yet this life stage, marked by profound physiological transitions and long-term health implication, presents…
Medpace Recognized as CRO Recipient of the 2025 SCRS Eagle Award
Medpace is honored to announce that we have been awarded the SCRS 2025 CRO Eagle Award. Since 2009, the SCRS...
[On-Demand Webinar] Advancing Obesity Clinical Development: Emerging Strategies for Next‑Gen Trials
With global recognition of obesity as a complex, chronic disease impacting over one billion people, advancements in obesity clinical development...
Bridging Early-Phase Insight to Late Phase Success | Inside Medpace’s New Phase I Unit Facility
With the launch of a newly built, state-of-the-art clinical pharmacology unit, Medpace strengthens its position as a strategic early phase...
Reflections from the 2025 ERA Congress: Insights on the Future of Kidney Research
Representatives from Medpace’s medical and operational teams engaged in critical discussions around trial innovation, therapeutic advances, and evolving standards of...
Q&A with Two Medpace Rheumatology Medical Experts: Innovations and Expert Insights
In this brief interview, we explore the expertise of two Medpace Rheumatologists.
Top 3 Key Takeaways from ENCALS 2025
Medpace Medical and Clinical Operations Experts Share Key Insights from the ENCALS Meeting
SNMMI 2025 Highlights | Radiopharmaceuticals Reshaping Oncology Trials
Radiopharmaceuticals are reshaping oncology trials through integrated imaging, dosimetry, and therapeutic precision. Following SNMMI, Medpace experts share considerations for biopharma Sponsors navigating the scientific, operational,…